STOCK TITAN
  1. Home
  2. News
  3. ADMA

Adma Biologics Inc - ADMA STOCK NEWS

Welcome to our dedicated news page for Adma Biologics (Ticker: ADMA), a resource for investors and traders seeking the latest updates and insights on Adma Biologics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Adma Biologics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Adma Biologics's position in the market.

News
ADMA Biologics Announces Third Quarter 2023 Financial Results and Provides Business Update
Rhea-AI Summary
ADMA Biologics, Inc. (Nasdaq: ADMA) announces 3Q2023 total revenues of $67.3 million, a 64% Y-o-Y increase, first-time positive GAAP net income of $2.6 million, and first-time positive operating cash flow of $12.0 million. Adjusted EBITDA grew to $12.7 million, with FY2023 total revenue guidance increased to more than $250 million. The company's momentum in 2023 has led to confidence in raised revenue guidance for 2024 and 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.8%
Tags
earnings
-
News
ADMA Biologics to Report Third Quarter 2023 Financial Results on November 8, 2023
Rhea-AI Summary
ADMA Biologics, Inc. will report its third quarter 2023 financial results on November 8, 2023, after the U.S. financial markets close. The management team will host a live conference call and webcast to discuss the financial results and other updates. Participants can register for the call to receive the dial-in numbers and unique PIN. The webcast will be available on the Company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.14%
Tags
conferences earnings
-
News
ADMA Biologics Announces Second Quarter 2023 Financial Results and Provides Business Update
Rhea-AI Summary
ADMA Biologics, Inc. (Nasdaq: ADMA) reported 2Q2023 Total Revenues of $60.1 Million, a 77% Y-o-Y Increase. The company also announced a 160% Q-o-Q Improvement in Adjusted EBITDA(1) and a 74% Y-o-Y Improvement in Adjusted Net Loss(2). FY2023 Total Revenue is now Expected to Exceed $240 Million, with Adjusted EBITDA Growth Expected Over the Remainder of 2023. FY2024 and 2025 Total Revenue Guidance Increased to $275 Million and $325 Million or More, Respectively. The company's second quarter 2023 financial results reflect strong growth and expansion in the immune deficient patient population, leading to increased revenue guidance for the coming years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.16%
Tags
earnings
News
ADMA Biologics to Report Second Quarter 2023 Financial Results on August 9, 2023
Rhea-AI Summary
ADMA Biologics, Inc. will report second quarter financial results on August 9, 2023, after the U.S. financial markets close. A live conference call and audio webcast will be held at 4:30 p.m. ET on the same day to discuss the results and provide updates. Participants can register for the call to receive dial-in numbers and a unique PIN. The call will be available for replay on the Company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.41%
Tags
conferences earnings
-
News
ADMA BioCenters Receives FDA Approval for its Ninth Plasma Collection Center, Located in Dallas, GA
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.76%
Tags
fda approval
-
News
ADMA Biologics Announces First Quarter 2023 Financial Results and Provides Business Update
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.92%
Tags
earnings
News
ADMA Biologics to Report First Quarter 2023 Financial Results on May 10, 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.45%
Tags
conferences earnings
-
News
ADMA Biologics Announces Amendment to Credit Agreement
Rhea-AI Summary
ADMA Biologics announces amendment to senior credit facility with Hayfin Capital Management, reducing interest rate and providing prepayment flexibility.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.51%
Tags
none
-
News
ADMA Biologics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.75%
Tags
earnings
News
ADMA Biologics to Report Fourth Quarter and Full Year 2022 Financial Results on March 23, 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
Stock ADMA logo
Adma Biologics Inc

Nasdaq:ADMA

ADMA Rankings

#2105 Ranked by Market Cap
#1004 Ranked by Stock Gains
N/A Ranked by Dividends

ADMA Stock Data

1.43B
223.72M
2.59%
76.26%
3.2%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Ramsey

About ADMA

adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.